On April 14, the Tianjin Medical Procurement Center issued a "Pre-Notification Announcement Regarding the Proposed Credit Rating Outcome for Hangzhou Saichen Biotechnology Co., Ltd." According to the announcement, the company has been suspended from its distribution qualifications in Tianjin for one year due to providing kickbacks or other improper benefits to various levels of medical institutions, centralized procurement organizations, and their staff during pharmaceutical sales and purchases.
Hangzhou Saichen Biotechnology Co., Ltd. was informed that, based on the guidelines of the National Healthcare Security Administration's Price and Procurement Center—specifically the "Operational Specifications for Pharmaceutical Pricing and Procurement Credit (2025 Edition)" and the "Discretionary Benchmark for Pharmaceutical Pricing and Procurement Credit Rating (2025 Edition)"—as well as relevant requirements from the Tianjin Medical Security Bureau's "Implementation Opinions on Establishing a Pharmaceutical Pricing and Procurement Credit Evaluation System," the center has conducted a credit rating assessment of the company's pricing misconduct. The proposed rating result has been notified, with detailed information available in the attached document.
The company is notified of the proposed credit rating result via this announcement. The notice is deemed served 15 days from the date of issuance. If there are any objections, the company must submit a written defense with official company seal and supporting materials within 20 days of receiving this notice. The credit rating decision will not be delayed due to any appeal submitted by the company.
Contact address: 4th Floor, Tianjin Chentang Technology Business District Service Center (No. 20 Dongting Road, Hexi District, Tianjin). Contact telephone: 022-24538156, 022-24538157. Tianjin Medical Procurement Center, April 14, 2026.
Comments